Pylarify
Ended Awarded Last action
- Contract number
- 36C25725N0121
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 17
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,900,169
Award facts
- Contract value 100% obligated
- $1,900,169.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $85,809 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $1,814,360 |
About this award
Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a $1.9M delivery order by Veterans Integrated Service Network 17 on January 1, 2025, with a completion deadline of December 31, 2025, for an increase in quantity of PYLARIFY (piflufolastat F-18). This award represents a firm fixed-price delivery order issued without set-aside designation under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) master contract. Performance will occur at the contractor's facility in North Billerica, Massachusetts. PYLARIFY is a radioactive diagnostic imaging agent used in positron emission tomography scans for the detection and localization of prostate cancer, providing critical diagnostic capabilities for federal healthcare providers serving the veteran population.
This delivery order is issued under Progenics' existing indefinite delivery vehicle with VISN 17, part of the contractor's broader portfolio of blanket purchase agreements and Federal Supply Schedule contracts with the Department of Veterans Affairs and Defense Health Agency. Progenics maintains an extensive federal contracting history as a primary supplier of radiopharmaceuticals and diagnostic imaging agents, with over 150 individual awards from multiple federal agencies and a recently awarded $290M Federal Supply Schedule contract with VISN 12 extending through March 2030. The firm fixed-price structure ensures cost certainty while supporting the VA's comprehensive oncology diagnostic imaging programs across its medical center network.
Quick answers
Who was awarded contract 36C25725N0121?
36C25725N0121 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 17 (Veterans Health Administration) on January 1, 2025.
How much is contract 36C25725N0121 worth?
The government has obligated $1,900,169 on 36C25725N0121.
Is contract 36C25725N0121 an order under another contract?
Yes. 36C25725N0121 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25725N0121 competed?
The extent of competition for 36C25725N0121 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award